Clinical Trial Detail

NCT ID NCT03667820
Title Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Texas Southwestern Medical Center
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: senior adult

No variant requirements are available.